Not only Frost, Vestor how about MerckThey manufacture our compound and Dr, Kulkarni is the lead investigator of our trial and Mercks NMIBC trial. They are trying to figure out what to do as I am typing. Do you think there is any chance they are going to see 100 percent efficacy on Keytruda. Remember, this is half dose and very possibly a complete immune response. If it reoccurs after 90 days, they just do it again. The Keytruda patients are getting treatments at intervals for months with no where near these results. Again Merck has spent billions on Keytruda.